Target intelligence / Profile preview

Labile copper pool (LCP) (LCP)

Target
LCP
Molecular classification
Metal ion pool, Other
01

Overview

The labile copper pool (LCP) refers to the fraction of intracellular copper that is loosely bound to low-molecular-weight ligands, such as glutathione and amino acids, making it readily available for biological processes [Ge et al., 2022; Faham et al., 2023]. Unlike the majority of cellular copper, which is tightly sequestered within metalloproteins, the LCP is dynamic and serves as a critical source for metallochaperones that deliver copper to essential enzymes like cytochrome c oxidase and superoxide dismutase [Blockhuys et al., 2017]. Maintaining the LCP within a narrow concentration range is vital, as copper is a potent redox-active metal that can catalyze the formation of reactive oxygen species via Fenton-like chemistry [Tsvetkov et al., 2022]. In diseases such as Wilson's disease, the LCP expands to toxic levels, leading to hepatic and neurological damage, whereas in many cancers, the pool is upregulated to support rapid proliferation and angiogenesis [European Association for the Study of the Liver, 2012; Blockhuys et al., 2017]. Pharmacological intervention targets the LCP through two primary strategies: chelation therapy to deplete the pool in cases of copper overload or cancer, and the use of copper ionophores to intentionally flood the pool and trigger cuproptosis, a copper-dependent form of regulated cell death [O'Day et al., 2013; Tsvetkov et al., 2022].

Other names
Exchangeable copper poolBioavailable copperRedox-active copperChelatable copperIntracellular copper pool
02

Mechanism of action

Modulation of intracellular copper levels via chelation to reduce bioavailability or ionophore-mediated transport to induce copper-dependent cytotoxicity (cuproptosis) [Tsvetkov et al., 2022; O'Day et al., 2013].

03

Biological functions

Redox signalingEnzyme cofactor homeostasisMitochondrial metabolismCell death regulation (Cuproptosis)Signal transduction
04

Disease associations

CancerWilson's diseaseMenkes diseaseNeurodegenerative diseaseAlzheimer's diseaseCardiovascular disease
05

Safety considerations

Systemic copper deficiency [Brewer, 2005]AnemiaNeutropeniaOff-target metal chelationNeurological worsening during initial treatment of Wilson's disease [European Association for the Study of the Liver, 2012]
06

Interacting drugs

Tetrathiomolybdate

6 more in the full profile.

07

Biomarkers

Exchangeable copper (CuEXC) [European Association for the Study of the Liver, 2012]Lipoylated DLAT [Tsvetkov et al., 2022]Copper-specific fluorescent probes [Ge et al., 2022]

Beyond the preview

Go deeper on Labile copper pool (LCP) (LCP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Labile copper pool (LCP) (LCP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call